Trials code hair loss in 3-7% of people on semaglutide or tirzepatide. One real-world survey put it at 70%. Both numbers are correct, they measure different things, and the gap explains why the shedding happens.
If you are finding more hair in the shower drain since starting semaglutide or tirzepatide, you have probably already met the two numbers that make this topic confusing. Trials code hair loss in somewhere around 3% to 7% of people. One survey of people actually taking these drugs found 70%.
The gap looks like a contradiction, and it gets used to argue both that the risk is inflated and that it is being hushed up. Neither claim survives a look at what was actually measured. The trials and the surveys are counting different things in different people, and the gap between them is itself the most useful clue about why the shedding happens.
The short version: hair shedding on incretin drugs is real, the biggest datasets agree it is mostly a response to how much and how fast weight comes off rather than a toxic effect on the follicle, and it is usually temporary. What the literature does not yet contain is a single trial designed to settle the question.
The randomized evidence was pooled this year in Diabetes Research and Clinical Practice. Nine interventional studies, seven of them randomized, covering 4,114 GLP-1 users: hair loss occurred about 3.3 times as often as on placebo, with a risk ratio of 3.25 and a confidence interval from 1.44 to 7.36. Restricted to trials in people with overweight or obesity, the ratio was 3.59. The pooled event rate on the drug was 3.9%.
Read that as a person rather than as a statistic and it says roughly one in twenty-five people, which matches the 3% to 7% range reported in the registration trials for these drugs.
The other number comes from a cross-sectional survey published in Skin Appendage Disorders, done between September 2024 and January 2025. Among 152 current and former users, 87.5% of them women, with a median BMI of 32.1 and a median weight loss of 15.9%, 70.4% reported shedding after starting the drug. Tirzepatide users reported it most (76.7%), then semaglutide (64%), then liraglutide (54.5%). People with pre-existing hair loss were excluded from the sample.
Both results are sound. One counts adverse events that a trial site records on a form; the other counts people who noticed a change in their hair and said so on a questionnaire, in a sample where nearly nine in ten were women losing a median of almost 16% of their body weight. A review in Acta Diabetologica published on 14 October 2026 frames the whole field with exactly this spread: 3% to 7% in controlled trials, over 70% in real-world cohorts.
Surveys are fragile, so the pooled numbers matter more.
A systematic review and meta-analysis in Skin Appendage Disorders, published in June, assembled 17 studies covering 1,091,743 patient-exposures. The pooled odds ratio for any non-scarring alopecia was 1.40 (95% CI 1.33 to 1.48), with no heterogeneity between the three cohort studies involved. Broken down by subtype: telogen effluvium, the diffuse shedding form, came in at an adjusted odds ratio of 1.76; androgenetic pattern thinning at 1.64; alopecia areata at 1.08, confidence interval crossing 1, meaning no association.
That last result is the useful one. Alopecia areata is the autoimmune form, where the immune system attacks follicles and produces patchy, potentially persistent loss. It is the subtype people fear most, and it is the one that keeps showing up as negative.
A propensity-matched TriNetX cohort study published in August, using US electronic records from 2018 to 2025, found the same pattern from the other direction. Semaglutide and tirzepatide users had higher odds of non-scarring hair loss diagnoses than matched non-users, with telogen effluvium odds elevated for semaglutide at three and five years and for tirzepatide at every follow-up window tested. Alopecia areata was used as a negative control and showed no association. And the people who developed hair loss were the ones with the lower follow-up BMI.
Pharmacovigilance points the same way with less precision. In the meta-analysis, reporting odds ratios were 2.46 for semaglutide and 1.73 for tirzepatide. A separate FAERS comparison published on 29 October 2026, covering 215,337 deduplicated reports from January 2022 to June 2026, found alopecia reported relatively more often with tirzepatide than semaglutide. Spontaneous reports cannot establish risk, and the authors of that study say so, but they can rank suspicion.
Telogen effluvium is the follicle being pushed from active growth into its resting phase by something systemic, followed by a noticeable shed. The candidates in this setting are all consequences of losing weight quickly: the caloric restriction itself, inadequate protein, micronutrient gaps, and the hormonal and metabolic shifts that come with large fat loss.
Each of these scales with the size and speed of the loss, and the data behave accordingly. In the Saudi survey, shedding was reported by 82.7% of people who had lost at least 15% of their weight, against 40% of those who had lost less than 5%. On multivariable analysis, greater weight loss stayed an independent predictor (OR 1.79, 95% CI 1.19 to 2.76), as did female sex (OR 3.57, 95% CI 1.20 to 11.11). The TriNetX finding of lower follow-up BMI among people with hair loss is the same signal from a different dataset.
Agent choice tracks weight loss too. A systematic review in Science Progress found the semaglutide signal looks dose-dependent, with weekly doses under 2 mg rarely implicated and the higher obesity-treatment doses implicated more often, while tirzepatide, which produces the largest losses, was the agent most often tied to telogen effluvium.
For the wider picture on how far these two drugs diverge in practice, our real-world comparison of semaglutide and tirzepatide (oriabiostack.com/blog/tirzepatide-vs-semaglutide-2026-real-world-data) covers outcomes beyond this one, and our breakdown of the low-dose tirzepatide study (oriabiostack.com/blog/low-dose-tirzepatide-2-5mg-vs-5mg-study) shows how much dose alone changes the effect.
There is a comparison that puts the 70% figure in perspective. The pooled incidence of hair loss after bariatric surgery, quoted in this year's clinical reviews, is 47% to 57%. Large, fast weight loss from any cause sheds hair at rates far above anything a drug side-effect form captures. That does not exonerate the drugs, but it does tell you which part of the exposure is doing the work.
Some researchers also propose direct routes: GLP-1 receptors in the white fat tissue that surrounds hair follicles, hormonal shifts, and nutrient deficiency acting on the follicle itself. These mechanisms are proposed in the reviews, not demonstrated in humans, and they remain hypotheses.
The consistent predictors across datasets are female sex, more than 10% weight loss, higher dose, and longer duration. The Acta Diabetologica review names female sex and weight reduction above 10% as the most robust predictors, which fits both the survey odds ratios and the fact that the survey sample was already 87.5% women.
The behavioral consequence is measurable: 39.7% of the affected participants in the survey gave shedding as their reason for stopping the drug, and 37.7% of them reported that it resolved after they stopped. Hair shedding is a real adherence problem, which is why dermatology commentary in the field now argues for warning people about it before it starts rather than after.
It is equally worth saying what this is not. It is not the patchy autoimmune loss that shows no association in either large analysis, and in most reported series it is diffuse, noticeable to the person, and reversible.
Two findings keep the story from being one-directional.
The same meta-analysis that found a 40% increase in non-scarring alopecia also reported that 58% of patients with central centrifugal cicatricial alopecia, a scarring form, improved while on these drugs. Smaller reports describe improvement in androgenetic thinning as well, which the Acta Diabetologica review attributes to metabolic normalization and reduced inflammation. Both are case-series level observations, and neither has been tested prospectively.
The larger caveat is in the design of the whole literature. As the commentary in Dermatologic Therapy put it, most of the evidence comes from pharmacovigilance databases and retrospective cohorts: "No prospective, controlled studies have specifically evaluated this issue." Causality has not been established for any of these agents. The survey is small, single-country and self-reported. Disproportionality analyses are distorted by what is in the news that month. Even the randomized pooling relies on adverse events that trials collected as secondary afterthoughts, with inconsistent definitions.
Nothing here argues for stopping a medication on your own; the survey's 37.7% resolution figure describes people who stopped under medical supervision, and the weight and metabolic benefits that came with the drug do not vanish because shedding started. It also puts this in the same family as our earlier look at what rapid weight loss does to bone: the body does not simply burn fat and leave the rest of it alone.
The clinical reviews converge on three moves. First, nutritional adequacy, with the practice review in Clinical Dermatology recommending protein of 1.2 to 2.0 g per kg of body weight per day and monitoring for gaps rather than guessing. Second, expectation setting: shedding that follows rapid loss tends to be self-limiting, and knowing that in advance keeps people from quitting over something that was going to reverse. Third, a clinician's view on the rest, since low-dose oral minoxidil appears in these reviews as an option some patients are offered, and it comes with its own trade-offs and a prescription attached.
The practical question people actually want answered is whether slowing the loss prevents it. Nobody has run that trial. The dose and weight gradients make it the obvious hypothesis, and it is consistent with the bariatric comparison, but a consistent hypothesis is not a result.
Evidence grade: C. The association is consistent across a randomized meta-analysis (RR 3.25), pooled cohorts covering more than a million patient-exposures (OR 1.40), and pharmacovigilance signals for both semaglutide and tirzepatide. The subtype pattern points at telogen effluvium driven by the magnitude and speed of weight loss, and the autoimmune subtype shows no link. Against that: no prospective controlled study has tested the question, the trial and survey numbers differ by an order of magnitude because they measure different things, and the mechanism is inferred rather than demonstrated. The direction of the finding is solid. Its size, and the share of it attributable to the drug rather than to the weight loss, are not.
Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026;237:113333. PMID 42155605.
Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disord. 2026. PMID 42621629.
Katragadda R, et al. Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study. Laryngoscope. 2026. PMID 42647098.
Alharbi S, Alkhalifah A. Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia. Skin Appendage Disord. 2026;12(4):283-95. PMID 41799300.
Arslan T. Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS. Endocrine. 2026;91(1):357. PMID 42955519.
Leite Júnior AC, Ribeiro Junior HL. GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox? Acta Diabetol. 2026. PMID 42873315.
Gupta AK, et al. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2):368504261444578. PMID 41998799.
Gupta AK, et al. Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review. Med Sci (Basel). 2026;14(6):652. PMID 42930571.
Bridges AG, Jackson T. Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice. Clin Dermatol. 2026. PMID 42767469.
Piraccini BM, et al. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. Dermatol Ther (Heidelb). 2026;16(7):3345-3360. PMID 42249225.
Zarabian N, et al. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms. Dermatol Surg. 2026;52(6S):S67-S71. PMID 42210891.
Disclaimer: This article is for educational purposes only and is not medical advice. Oria exists to give you the science behind peptide and metabolic therapies so you can have a better conversation with a licensed physician. Never start, stop, or change a prescribed medication based on what you read here. Talk to your doctor about your individual risk, your rate of weight loss, and whether anything you are seeing warrants a check.
